Distinct clinical features of urothelial carcinoma with low-expressing human epidermal growth factor receptor 2 status.

IF 1.9 3区医学 Q4 ANDROLOGY

Translational andrology and urology Pub Date : 2024-11-30 Epub Date: 2024-11-28 DOI:10.21037/tau-24-354

Xiaochen Huang, Shaoqiu Li, Tingting Yang, Dawei Ma, Hongzhou Cai, Xinyu Xu, Yi Zhang

{"title":"Distinct clinical features of urothelial carcinoma with low-expressing human epidermal growth factor receptor 2 status.","authors":"Xiaochen Huang, Shaoqiu Li, Tingting Yang, Dawei Ma, Hongzhou Cai, Xinyu Xu, Yi Zhang","doi":"10.21037/tau-24-354","DOIUrl":null,"url":null,"abstract":"Background: Some urothelial carcinoma patients are ineligible for platinum-based chemotherapy, necessitating exploration of other effective therapeutic strategies. Human epidermal growth factor receptor 2 (HER2) protein overexpression, gene amplification or mutations exist in urothelial carcinoma. Our study is to investigate the correlation of three-tier assessment of HER2 expression with clinical pathological characteristics and prognosis of urothelial carcinoma.Methods: HER2 expression in 75 urothelial carcinomas from Jiangsu Cancer Hospital was re-scored by immunohistochemistry and fluorescence in situ hybridization according to HER2 three-tier assessment standards. Its relationship with various pathological parameters of urothelial carcinoma and its correlation with prognosis were analyzed. And validate in The Cancer Genome Atlas (TCGA) cohort.Results: HER2 expression was observed in 82.7% (62/75) of urothelial carcinoma patients, of which HER2-low expression accounted for 61.3% (46/75). HER2 expression was significantly correlated with the tumor-nodes-metastasis (TNM) stage of urothelial carcinoma (P=0.043) and HER2-low was an independent poor prognostic factor for patients with urothelial carcinoma (P=0.04). Follow-up showed that HER2-low patients had the worst prognosis compared with HER2-negative (P=0.02) and HER2 positive (P=0.02) and also had the highest progression rate in TCGA cohort (P=0.02); receiver operator characteristic (ROC) model suggested HER2-low could effectively predict prognosis.Conclusions: HER2 expression is closely related to the TNM stage of urothelial carcinoma; HER2 three-tier assessment can effectively predict clinical prognosis of urothelial carcinoma.","PeriodicalId":23270,"journal":{"name":"Translational andrology and urology","volume":"13 11","pages":"2419-2429"},"PeriodicalIF":1.9000,"publicationDate":"2024-11-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11650335/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational andrology and urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tau-24-354","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/28 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ANDROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Some urothelial carcinoma patients are ineligible for platinum-based chemotherapy, necessitating exploration of other effective therapeutic strategies. Human epidermal growth factor receptor 2 (HER2) protein overexpression, gene amplification or mutations exist in urothelial carcinoma. Our study is to investigate the correlation of three-tier assessment of HER2 expression with clinical pathological characteristics and prognosis of urothelial carcinoma.

Methods: HER2 expression in 75 urothelial carcinomas from Jiangsu Cancer Hospital was re-scored by immunohistochemistry and fluorescence in situ hybridization according to HER2 three-tier assessment standards. Its relationship with various pathological parameters of urothelial carcinoma and its correlation with prognosis were analyzed. And validate in The Cancer Genome Atlas (TCGA) cohort.

Results: HER2 expression was observed in 82.7% (62/75) of urothelial carcinoma patients, of which HER2-low expression accounted for 61.3% (46/75). HER2 expression was significantly correlated with the tumor-nodes-metastasis (TNM) stage of urothelial carcinoma (P=0.043) and HER2-low was an independent poor prognostic factor for patients with urothelial carcinoma (P=0.04). Follow-up showed that HER2-low patients had the worst prognosis compared with HER2-negative (P=0.02) and HER2 positive (P=0.02) and also had the highest progression rate in TCGA cohort (P=0.02); receiver operator characteristic (ROC) model suggested HER2-low could effectively predict prognosis.

Conclusions: HER2 expression is closely related to the TNM stage of urothelial carcinoma; HER2 three-tier assessment can effectively predict clinical prognosis of urothelial carcinoma.

查看原文本刊更多论文

低表达人表皮生长因子受体2状态尿路上皮癌的独特临床特征。

背景：一些尿路上皮癌患者不适合铂基化疗，需要探索其他有效的治疗策略。人表皮生长因子受体2 （HER2）蛋白在尿路上皮癌中存在过表达、基因扩增或突变。我们的研究是探讨HER2三层表达与尿路上皮癌临床病理特征及预后的相关性。方法：采用免疫组织化学和荧光原位杂交技术，按照HER2三级评价标准对江苏省肿瘤医院75例尿路上皮癌患者的HER2表达进行重新评分。分析其与尿路上皮癌各病理参数的关系及与预后的关系。并在癌症基因组图谱（TCGA）队列中进行验证。结果：82.7%（62/75）的尿路上皮癌患者存在HER2表达，其中HER2低表达占61.3%（46/75）。HER2表达与尿路上皮癌TNM分期有显著相关性（P=0.043）， HER2低水平是尿路上皮癌患者预后不良的独立因素（P=0.04）。随访显示，与HER2阴性患者（P=0.02）和HER2阳性患者（P=0.02）相比，HER2低患者预后最差，病程进展率也最高（P=0.02）；ROC模型提示HER2-low可有效预测预后。结论：HER2表达与尿路上皮癌TNM分期密切相关；HER2三级评价能有效预测尿路上皮癌的临床预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Translational andrology and urology Medicine-Urology

CiteScore

4.10

自引率

5.00%

发文量

期刊介绍： ranslational Andrology and Urology (Print ISSN 2223-4683; Online ISSN 2223-4691; Transl Androl Urol; TAU) is an open access, peer-reviewed, bi-monthly journal (quarterly published from Mar.2012 - Dec. 2014). The main focus of the journal is to describe new findings in the field of translational research of Andrology and Urology, provides current and practical information on basic research and clinical investigations of Andrology and Urology. Specific areas of interest include, but not limited to, molecular study, pathology, biology and technical advances related to andrology and urology. Topics cover range from evaluation, prevention, diagnosis, therapy, prognosis, rehabilitation and future challenges to urology and andrology. Contributions pertinent to urology and andrology are also included from related fields such as public health, basic sciences, education, sociology, and nursing.